Massachusetts to Pay for Zolgensma on One Condition: It Must Work
Massachusetts' Medicaid program, MassHealth, has inked a conditional deal for Novartis' $2 million one-time spinal muscular atrophy (SMA) gene therapy, [...]
Advertisement
Massachusetts' Medicaid program, MassHealth, has inked a conditional deal for Novartis' $2 million one-time spinal muscular atrophy (SMA) gene therapy, [...]
